ERBB2 and breast cancer: In Her2 inhibitor-sensitive Her2-positive BC cells, siMCL1 induced significantly higher rates of cell death when compared with siHER2, indicating the existence of Mcl-1-dependent survival pathways in Her2-positive BC cells, which are independent of the Mcl-1–Her2 axis (Fig. 5a).